Presentation, Management, and Outcomes of Patients With Giant Pheochromocytoma
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae612 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Bahar Bahrani Fard und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Pheochromocytoma, Adrenal Gland Neoplasms, Adrenalectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Context
Data on giant pheochromocytomas (PHEOs), defined based on size 10 cm or greater, are scarce.
Objective
This work aimed to compare presentation, management, and outcomes of patients with giant vs non–giant PHEOs.
Methods
A retrospective cohort study was conducted in a referral center from 2000 to 2023. Consecutive patients with giant PHEOs and randomly chosen patients with non–giant PHEO (referents) were studied at a 1:6 ratio. Outcomes included perioperative complications, metastases, and mortality.
Results
Of 828 patients with PHEOs, 31 (3.7%) had giant PHEO (median size 12 cm, interquartile range [IQR] 10.0-13.5 cm). In comparison to referents (n = 186, median size 4 cm, IQR, 2.9-5.0 cm), patients with giant PHEO had more symptoms of catecholamine excess (median of 2 vs 1; P = .04) and presented with a higher prevalence of severe catecholamine excess (76% vs 30%; P < .0001). Adrenalectomy was performed in 94% of patients with giant PHEOs and 100% of referents. In addition to preoperative α-adrenergic blockade (89%), metyrosine was used in 14 (7%) patients, mostly in patients with giant PHEOs (26% vs 3%; P < .0001). Patients with giant PHEOs had a higher perioperative complication rate (31% vs 10%; P = .004). During a median follow-up of 3 years, metastases developed at a higher rate in patients with giant PHEOs (45% vs 4% in referents; P < .0001). Disease-specific mortality was 7% in patients with giant PHEOs and 0% in referents (P = .02).
Conclusion
Patients with giant PHEOs compared to referents were more symptomatic, had a higher degree of catecholamine excess, and had a higher rate of perioperative complications. Almost half of patients with giant PHEOs developed metastases, warranting close follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA.
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Bahar Bahrani Fard, Nasrin Nikravangolsefid, William F Young, Irina Bancos
Zitieren
APA
Bahrani Fard, B., Nikravangolsefid, N., Maroun, J. W., Cross, A., Foster, T., McKenzie, T. J., Dy, B., Lyden, M., Young, W. F., & Bancos, I. (2025). Presentation, Management, and Outcomes of Patients With Giant Pheochromocytoma. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae612
Vancouver
Bahrani Fard B, Nikravangolsefid N, Maroun JW, Cross A, Foster T, McKenzie TJ, et al. Presentation, Management, and Outcomes of Patients With Giant Pheochromocytoma. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae612
BibTeX
@article{BahraniFard2025,
author = {Bahrani Fard, Bahar and Nikravangolsefid, Nasrin and Maroun, Justin W and Cross, Ashton and Foster, Trenton and McKenzie, Travis J and Dy, Benzon and Lyden, Melanie and Young, William F and Bancos, Irina},
title = {Presentation, Management, and Outcomes of Patients With Giant Pheochromocytoma},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae612}
}
EUVIMED